9594results about "Urinary disorder" patented technology

The invention discloses a xanthine oxidase inhibitory peptide with a kidney improving function and application thereof, and belongs to the technical field of biological medicines.The xanthine oxidase inhibitory peptide is screened out by conducting enzymolysis, separation and purification on litopenaeus vannamei processing by-products and utilizing a molecular docking technology, the amino acid sequence of the xanthine oxidase inhibitory peptide is Pro-Leu-Gly-Pro-Pro-Pro, and the amino acid sequence of the xanthine oxidase inhibitory peptide is Pro-Leu-Gly-Pro-Pro-Pro. And the half inhibition concentration of the polypeptide is 2.356 + / -0.2448 mM. The xanthine oxidase inhibitory peptide is proved to have an improvement effect on hyperuricemia mice, the improvement effect is mainly characterized by reducing the content of serum uric acid, creatinine and urea nitrogen of the hyperuricemia mice, inhibiting the activity of xanthine oxidase (XOD) in serum and livers of the mice, inhibiting synthesis of uric acid and improving kidney injury of the mice, and Toxinpred prediction shows that the xanthine oxidase inhibitory peptide has the effect of inhibiting the activity of xanthine oxidase (XOD) in the serum and livers of the mice. The xanthine oxidase inhibitory peptide is free of toxic and side effects, so that the xanthine oxidase inhibitory peptide has a wide application prospect in preparation of food or drugs for improving renal functions.

The invention discloses a xanthine oxidase inhibitory peptide with uric acid reducing activity and application thereof, and belongs to the technical field of biological medicines.The xanthine oxidase inhibitory peptide is obtained by conducting enzymolysis, separation and purification on processing byproducts such as litopenaeus vannamei heads and shells with xanthine oxidase inhibitory activity. The xanthine oxidase inhibitory peptide is screened by using a molecular docking technology, and the amino acid sequence of the xanthine oxidase inhibitory peptide is Pro-Pro-Val-Pro-Pro-Pro. The xanthine oxidase inhibitory peptide has an XOD (X-Oxidase) half inhibitory concentration of 3.181 + / -0.1786 mM. The invention further proves that the xanthine oxidase inhibitory peptide has a certain improvement effect on hyperuricemia mice, and the xanthine oxidase inhibitory peptide mainly has the effects of reducing the content of serum uric acid, creatinine and urea nitrogen of the hyperuricemia mice, inhibiting the activity of xanthine oxidase (XOD) in serum and liver of the mice, inhibiting synthesis of uric acid and improving kidney injury of the mice, and the xanthine oxidase inhibitory peptide has a certain improvement effect on the hyperuricemia mice through Toxinpred prediction. The xanthine oxidase inhibitory peptide uric acid reducing peptide is free of toxic and side effects and has a wide market application prospect.

This disclosure relates to administration of a combination of: 1) about 100-110 mg, about 104-106 mg, or about 105 mg of bupropion hydrochloride, or a molar equivalent amount of a free base form or another salt form of bupropion; and 2) about 40-50 mg, about 44-46 mg, or about 45 mg of dextromethorphan hydrobromide, or a molar equivalent amount of a free base form or another salt form of dextromethorphan in certain patient populations, such as patients having moderate renal impairment, patients receiving a concomitant strong CYP2D6 inhibitor, patients who are known CYP2D6 poor metabolizers, those in need of an NMDA antagonist that does not cause dissociation, and those at risk of QT prolongation.

Disclosed herein are antibodies that specifically bind to Gal3 and methods of use thereof. In some embodiments, also described herein are methods of inducing immune activation or promoting T cell or Natural Killer cell proliferation with an antibody that specifically binds to Gal3. Also disclosed herein are methods and compositions of reducing fibrosis or propensity thereof in a tissue with antibodies that specifically bind to Gal3. In some cases, the anti-Gal3 antibody also disrupts the interaction between Gal3 and TIM-3.

This disclosure relates to administration of a combination of: 1) about 100-110 mg, about 104-106 mg, or about 105 mg of bupropion hydrochloride, or a molar equivalent amount of the free base form or another salt form of bupropion; and 2) about 40-50 mg, about 44-46 mg, or about 45 mg of dextromethorphan hydrobromide, or a molar equivalent amount of the free base form or another salt form of dextromethorphan in certain patient populations, such as patients having moderate renal impairment, patients receiving a concomitant strong CYP2D6 inhibitor, patients who are known CYP2D6 poor metabolizers, those in need of an NMDA antagonist that does not cause dissociation, and those at risk of QT prolongation.

A class of compounds and the use thereof in a drug. Specifically, the present invention relates to a class of new compounds, a pharmaceutical composition containing the compounds, a method for preparing the compounds, and the use of the compounds or the pharmaceutical composition in the preparation of a drug for treating GLP-1 receptor agonist-mediated diseases and / or disorders, particularly the use in the preparation of a drug for treating diabetes, non-alcoholic fatty liver disease, obesity, myocardial infarction, heart failure, diabetic nephropathy, Parkinson's disease and Alzheimer's disease.

The principles and embodiments of the present disclosure relate to a composition for improving kidney function in an adult patient with hepatorenal syndrome with rapid reduction in kidney function. The composition includes terlipressin acetate having a formula of C52H74N16O15S2·(C2H4O2)n, where n is 2.8.

This disclosure relates to administration of a combination of: 1) about 100-110 mg, about 104-106 mg, or about 105 mg of bupropion hydrochloride, or a molar equivalent amount of the free base form or another salt form of bupropion; and 2) about 40-50 mg, about 44-46 mg, or about 45 mg of dextromethorphan hydrobromide, or a molar equivalent amount of the free base form or another salt form of dextromethorphan in certain patient populations, such as patients having moderate renal impairment, patients receiving a concomitant strong CYP2D6 inhibitor, patients who are known CYP2D6 poor metabolizers, those in need of an NMDA antagonist that does not cause dissociation, and those at risk of QT prolongation.

The invention provides annular multi-tandem PCSK9 siRNA, which comprises at least one positive-sense strand sequence and at least one spacer sequence. The sense strand of the cyclic siRNA is derived from an engineered parent DNA template containing all essential sequences, comprising in the following order a first cyclization element, optionally at least one first restriction enzyme recognition sequence, at least one target sequence, optionally at least one second restriction enzyme recognition sequence, and a second cyclization element. The annular multi-tandem RNA positive-sense strand can combine and deliver a plurality of antisense strand RNAs, and the combination of the positive-sense strand and the antisense strand is increased while the stability advantage of the annular RNA is utilized.

The invention discloses a plant lactobacillus. The plant lactobacillus has the characteristic of efficiently tolerating 30% (w / v) cistanche substrate. The invention also discloses a medicinal and edible composition consisting of 85 parts of cistanche deserticola, 5 parts of rehmannia, 5 parts of fructus alpiniae oxyphyllae and 5 parts of Chinese yam, the composition is fermented by using plant lactobacillus, and the cistanche deserticola fermentation liquor is prepared by adopting a multi-stage temperature fermentation process to ferment for 16 hours. A non-targeted metabonomics result shows that the phytobacterium plantarum activates an upstream channel for synthesis of phenylethanoid glycoside substances, and the abundance of forsythiaside B is increased by 133 times compared with that before fermentation. The fermentation liquor can achieve the functions of reproductive anti-aging, kidney protection and body endurance improvement by down-regulating COX-2a and TGF-beta-1 gene expression.

Some aspects of this disclosure provide strategies, systems, reagents, methods, and kits that are useful for the targeted editing of nucleic acids, including editing a single site within the genome of a cell or subject, e.g., within the human genome. In some embodiments, fusion proteins of Cas9 and nucleic acid editing proteins or protein domains, e.g., deaminase domains, are provided. In some embodiments, methods for targeted nucleic acid editing are provided. In some embodiments, reagents and kits for the generation of targeted nucleic acid editing proteins, e.g., fusion proteins of Cas9 and nucleic acid editing proteins or domains, are provided.

The invention provides a compound of a GLP-1R agonist or modulator with a structure as shown in a formula (I).

Relates to a multispecific antibody or antigen binding fragment specifically binding to LIGHT and GM-CSFR alpha, a composition containing the antibody or antigen binding fragment specifically binding to LIGHT and the antibody or antigen binding fragment specifically binding to GM-CSFR alpha, a pharmaceutical composition containing the multispecific antibody or composition, and a preparation method and application thereof. Including methods of using the same to prevent and treat inflammatory, respiratory or autoimmune diseases.

The invention provides a benzofuranone compound as well as a pharmaceutical composition and application thereof, and relates to the technical field of medicines. The benzofuranone compound is a compound as shown in a formula I, a stereoisomer thereof, a tautomer thereof, a crystalline hydrate thereof, a solvate thereof, a prodrug thereof or a pharmaceutically acceptable salt thereof. The benzofuranone compound and the pharmaceutical composition and the pharmaceutical preparation prepared from the benzofuranone compound can prevent or treat organ injury diseases, and have good treatment effects in kidney injury, liver injury, lung injury, brain injury and heart injury.

The invention relates to the technical field of biological medicine, in particular to a ferroptosis inhibition type phospholipid-like material and application thereof. The ferroptosis inhibition type phospholipid-like material is one of the following structural general formulas (1)-(5). The biomimetic phospholipid-like ferroptosis inhibitor has a long retention characteristic in main positions (cell membranes, endoplasmic reticulum and other organelle membranes) of cell ferroptosis, so that the ferroptosis inhibition efficiency is remarkably improved. The novel phospholipid-like material not only can be used as an active drug molecule, but also can be used as a pharmaceutic adjuvant for constructing drug delivery carriers such as lipidosome and micelle and implant coatings, and is suitable for various administration routes such as oral administration, injection and local administration. The novel biomimetic ferroptosis inhibitor can efficiently relieve cell ferroptosis and has a wide application prospect in the field of treating or retarding ferroptosis-related diseases.

The present invention relates to the field of pharmaceutical technology, and more particularly to the use of Morinda officinalis polysaccharide in preparing a product for improving renal fibrosis. The preparation method of the Morinda officinalis polysaccharide comprises the following steps: (1) extracting Morinda officinalis from water, filtering, and obtaining a supernatant; (2) subjecting the supernatant to alcohol precipitation to obtain a precipitate; and (3) dialyzing and removing protein from the precipitate. The Morinda officinalis polysaccharide has a significant therapeutic effect in improving renal fibrosis.

The invention discloses an M2M-SeMSN-coated C176 nano-particle, a preparation method and application thereof, the nano-particle comprises an STING inhibitor C176 and a carrier, and the carrier is based on an M2 macrophage membrane and a selenium-bridged mesoporous silica nano-particle. Specifically, the M2M-SeMSN-coated C176 nano-particles are obtained by loading an STING inhibitor C176 by using a selenium-bridged mesoporous silica nano-particle SeMSN and M2 macrophage cell membrane. The invention further discloses a preparation method of the M2M-SeMSN-coated C176 nano-particles. The M2M-SeMSN-coated C176 nanoparticles can be used for preparing a medicine for treating acute kidney injury.

Disclosed are small molecule inhibitors of αvβ6 integrin, and methods of using them to treat a number of diseases and conditions.

The invention belongs to the field of biological medicines, and particularly discloses application of a Ptprj agonist GJ103 in preparation of a medicine for treating acute kidney injury (AKI) induced by cisplatin. In-vivo and in-vitro experiments prove that the GJ103, by activating Ptprj, can significantly down-regulate expression of pro-apoptotic protein Bax and Cleved Caspase-3, up-regulate anti-apoptotic protein Bcl2 and reduce infiltration of inflammatory factors TNF-alpha and IL-6, so that apoptosis and inflammatory response of renal tubular epithelial cells are relieved. In in-vivo experiments, GJ103 (20-40mg / kg / day) can reduce serum creatinine and urea nitrogen levels of cis-platinum model mice and improve pathological injuries such as renal tubule dilatation; in in-vitro experiments, 20-40 [mu] M of GJ103 can inhibit apoptosis of renal tubular epithelial cells and reduce expression of renal injury markers NGAL and Kim-1. The pharmaceutical composition contains GJ103 and a pharmaceutical carrier, the preparation form can be a 4mg / mL injection (the purity is greater than or equal to 99.46%) or an oral preparation, and a new strategy is provided for clinical treatment of cisplatin renal toxicity.

The invention provides a method for efficiently extracting tea polyphenol and tea polysaccharide and application, and belongs to the technical field of plant extraction.The extraction method comprises the following steps that tea leaves are pre-cooled and rolled and cut to obtain pretreated tea leaves, then the pretreated tea leaves are added into water to be mixed, biological enzyme is added for ultrasonic enzymolysis, filtering is conducted, and filtrate and tea residues are obtained; adding tea residues into water, mixing, adding an auxiliary agent, and carrying out low-temperature plasma treatment and filtration to obtain a filtrate; combining the filtrates, concentrating, precipitating, centrifuging, and collecting precipitate and supernate; washing and drying the precipitate to obtain a tea polysaccharide extract; and concentrating, extracting, adsorbing, eluting, re-concentrating and drying the supernate to obtain the tea polyphenol extract. The extraction method disclosed by the invention can be used for efficiently extracting the tea polyphenol and the tea polysaccharide in the tea leaves, the product yield and purity are high, and the tea polyphenol and the tea polysaccharide can be used for preparing health-care products for relieving diabetes and polyuria.

The invention discloses application of oligopeptide in preparation of a medicine for treating and / or preventing diabetic nephropathy. The oligopeptides comprise oligopeptides with the amino acid sequence of SEQ ID NO: 1: LNLYP and derivative sequences or conservative substitution variants of the oligopeptides. The oligopeptide can significantly improve renal function indexes of mice with diabetic nephropathy, such as UACR, serum creatinine, urea nitrogen and the like, enhance podocyte barrier integrity and inhibit accumulation of advanced glycosylation end products AGEs in kidney tissues, and provides a basis for development of novel drugs for treating diabetic nephropathy.

Provided herein are pharmaceutical compositions comprising carotenoids, including liposomes that encapsulate carotenoids including ionizable carotenoids such as trans-crocetin. The provided compositions have uses in treating diseases, disorders and conditions associated with, but not limited to, infection, endotoxemia, inflammation, sepsis, ischemia, hypoxia, shock, stroke, lung injury, wound healing, traumatic injury, reperfusion injury, cardiovascular disease, kidney disease, liver disease, inflammatory disease, metabolic disease, pulmonary disorders, blood related disorders and hyperproliferative diseases such as cancer. Methods of making, delivering, and using the pharmaceutical compositions are also provided.

The invention belongs to the technical field of biological medicines, and particularly relates to a morinda officinalis-synanthrin composition and application thereof in renal fibrosis products. The radix morindae officinalis-synanthrin composition provided by the invention is prepared from radix morindae officinalis polysaccharide, synanthrin and water, the synergistic effect of the two polysaccharides can be exerted, the physical and chemical properties and biological activity of the radix morindae officinalis-synanthrin composition can be improved, the metabolic rate of the kidney to urea nitrogen creatinine can be remarkably increased, the fibrosis positive area can be remarkably reduced, and the bioavailability of the radix morindae officinalis-synanthrin composition is improved. The traditional Chinese medicine composition has a remarkable effect on treating renal fibrosis diseases. The raw materials of the composition are based on natural polysaccharides, so that the composition has good safety and degradability, and meets the high requirement of the medical field on the safety of biological materials. Compared with an existing single component, the compound design can achieve the multi-target effect, the treatment effect is remarkably improved, and the compound medicine has the large market competitive advantage.

Provided are compounds having metalloenzyme modulating activity, and methods of treating diseases, disorders, or symptoms thereof mediated by such metalloenzymes. In some embodiments, a provided compound is a compound of Formula I,or a pharmaceutically acceptable salt thereof. In some embodiments, a provided method is a method of alleviating or abating a disorder or disease associated with aldosterone synthase (CYP11B2) or ameliorating a symptom thereof.

The invention discloses a stem cell preparation for improving function degeneration of prostatitis and a preparation method and application thereof, and relates to the technical field of stem cells, the stem cell preparation is prepared from mesenchymal stem cells UC-MSCs and ADSCs according to the cell concentration ratio of 1: 2, hyaluronic acid hydrogel is used as a delivery carrier, and the stem cell preparation is prepared from the mesenchymal stem cells UC-MSCs and ADSCs according to the cell concentration ratio of 1: 2. And two key auxiliary components of juniperus formosana extract and mulberry extract are introduced. Wherein the optimal combination of the UC-MSCs and the ADSCs significantly enhances the anti-inflammatory ability and the tissue regeneration effect; the hyaluronic acid hydrogel carrier system effectively improves the targeting delivery efficiency of the stem cells and prolongs the action time; the two natural active components of the juniperus formosana extract and the mulberry extract synergistically improve the local microenvironment of prostate and inhibit inflammatory response and fibrosis process. The stem cell preparation developed through a multi-component synergistic effect mechanism has the characteristics of high targeting property, lasting treatment effect, high safety and the like, and a new strategy is provided for clinical treatment of prostatitis.

The invention discloses a neutralizing nucleic acid aptamer for targeted inhibition of a B cell activating factor and application of the neutralizing nucleic acid aptamer in treatment of systemic lupus erythematosus. The neutralizing aptamer disclosed by the invention can be used for efficiently inhibiting the combination of BAFF and specific receptors on a B cell membrane, including a BAFF receptor (BAFF-R), a human calcium regulatory cyclophilin ligand interaction molecule (TACI) and a B cell maturation antigen (BCMA), so that the proportion of plasma cells, plasma mother cells and hair growth center B cells is reduced, and finally, the generation and secretion of autoantibodies are reduced; the compound has a targeted therapeutic effect on systemic lupus erythematosus. Compared with an existing biological agent for neutralizing BAFF, the neutralizing nucleic acid aptamer has the advantages of being high in specificity, high in affinity, easy to synthesize, low in immunogenicity, low in cost, capable of being designed and programmed and the like, is a potential novel nucleic acid preparation for SLE targeted therapy, and has a good clinical transformation application prospect.

To provide a new composition for increasing expression of the Klotho gene and an application thereof.SOLUTION: The present disclosure provides, in one aspect, the following invention: a composition for enhancing expression of the human Klotho / KL gene, the composition comprising at least a portion of a protein belonging to the TNF superfamily or a nucleic acid encoding at least a portion of the protein.SELECTED DRAWING: None

Disclosed in the present invention are a monoclonal antibody against an interleukin-6 protein and the use thereof. The present invention provides a nucleic acid molecule, a vector, a cell, a composition, a product, a bispecific antibody, a CAR, an antibody-drug conjugate and a pharmaceutical composition comprising an anti-IL-6 monoclonal antibody or an antigen-binding fragment thereof; and further provides the use of the monoclonal antibody or the antigen-binding fragment thereof, the nucleic acid molecule, the vector, the cell, the composition and the product in the detection of IL-6 or a nucleic acid fragment encoding same, in the preparation of a product for detecting IL-6, in a pharmaceutical composition for preventing or treating diseases related to abnormal IL-6 expression, and in the preparation of a pharmaceutical composition for regulating the expression level or activity of IL-6.